Hepatitis B Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates

DelveInsight's "Hepatitis B Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hepatitis B, historical and forecasted epidemiology as well as the Hepatitis B market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hepatitis B market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatitis B Market Forecast
https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Hepatitis B Market Report:
• The Hepatitis B market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In March 2025, Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company utilizing its ARCUS® platform to develop in vivo therapies for diseases with high unmet needs, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PBGENE-HBV. This lead program focuses on curing chronic hepatitis B by eliminating cccDNA, the main source of HBV replication, and inactivating integrated HBV DNA in liver cells. Precision is preparing U.S. trial sites for patient enrollment in the ELIMINATE-B trial, which addresses over one million people living with chronic hepatitis B in the U.S. The study is already enrolling patients in Moldova, Hong Kong, and New Zealand, with Phase 1 clinical activities soon to begin in the U.S. at the Liver Center, Massachusetts General Hospital.
• In February 2025, Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing firm leveraging its ARCUS® platform to develop in vivo therapies for diseases with high unmet needs, has reported initial data from the first dosing of PBGENE-HBV in cohort 1 of the ELIMINATE-B trial, which represents the lowest dose group. The study aims to assess PBGENE-HBV across multiple escalating dose levels, with three administrations per level, in HBeAg-negative chronic Hepatitis B patients.
• In October 2024, Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company leveraging its proprietary ARCUS® platform to develop in vivo gene editing therapies for complex gene modifications, announced that it has received Clinical Trial Application (CTA) approval in Moldova for its lead candidate, PBGENE-HBV. PBGENE-HBV is Precision's exclusive in vivo gene editing program aimed at curing chronic hepatitis B by eliminating cccDNA, a key source of replicating hepatitis B virus (HBV), and inactivating integrated HBV DNA in hepatocytes. The company has launched the Phase 1 clinical program and is preparing to begin patient dosing.
• In October 2024, Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company focused on developing innovative immunotherapeutic candidates to direct T cells in disease control, has announced the completion of enrollment for two clinical trials: HBV003, a Phase 2b trial of VTP-300 in adults with chronic hepatitis B (CHB), and PCA001, a Phase 1 trial of VTP-850 in men with rising prostate-specific antigen (PSA) following definitive local therapy for prostate cancer (i.e., biochemical recurrence).
• In April 2024, The Philippine Food and Drug Administration (PFDA) has approved the clinical trial for YS Biopharma's YS-HBV-002, an immunotherapeutic vaccine designed to treat chronic hepatitis B virus (HBV) infection.
• According to estimates provided by the Hepatitis B Foundation, National Foundation for Infectious Diseases (2018), and the CDC, the total number of chronic hepatitis B cases is estimated to be approximately 2.2 million or higher.
• In 2023, the United States recorded approximately 881,700 diagnosed prevalent cases of chronic hepatitis B.
• In the European Union's four largest countries plus the United Kingdom (EU4+UK), Germany had the highest diagnosed prevalence of chronic hepatitis B, totaling approximately 175,000 cases, whereas Spain had the lowest diagnosed prevalence, with around 52,500 cases in 2023.
• Key Hepatitis B Companies: Arbutus Biopharma, GSK/Ionis Pharmaceuticals, Vir Biotechnology, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp, Brii Biosciences Limited, Vir Biotechnology, Inc., Arbutus Biopharma Corporation, Erasmus Medical Center, Daewoong Pharmaceutical Co., Ascletis Pharmaceuticals, Gilead Sciences, Fujian Akeylink Biotechnology, Chia Tai Tianqing Pharma, Janssen Research & Development, LLC, Hoffmann-La Roche, Chengdu Suncadia Medicine, Suzhou Ribo Life Science, Arbutus Biopharma Corporation, Ascentage Pharma Group, and others
• Key Hepatitis B Therapies: AB-729, Bepirovirsen, Elebsiran, GSK3965193, DA-2803, ChAdOx1-HBV, Undiluted I.V.-Hepabig inj(GC5103), PEG-IFNα, VIR-3434, AB-729, ISA104, Vemliver tablet, ASC22, TAF, GST-HG131, TQA3605 tablets, JNJ-73763989, Nucleos(t)ide (NUC), HRS9950 tablets, RBD1016, Imdusiran, APG-1387, and others
• The Hepatitis B epidemiology based on gender analyzed that in 2023, there were more diagnosed prevalent cases of chronic hepatitis B (CHB) among males than females in the United States.
• The Hepatitis B market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatitis B pipeline products will significantly revolutionize the Hepatitis B market dynamics.

Hepatitis B Overview
Hepatitis B is a viral infection that primarily affects the liver, caused by the hepatitis B virus (HBV). It can lead to both acute and chronic liver disease and is one of the most common infectious diseases worldwide. Hepatitis B can be transmitted through contact with infected blood, semen, or other body fluids, as well as from mother to baby during childbirth.

Get a Free sample for the Hepatitis B Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hepatitis B Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hepatitis B Epidemiology Segmentation:
The Hepatitis B market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Hepatitis B
• Prevalent Cases of Hepatitis B by severity
• Gender-specific Prevalence of Hepatitis B
• Diagnosed Cases of Episodic and Chronic Hepatitis B

Download the report to understand which factors are driving Hepatitis B epidemiology trends @ Hepatitis B Epidemiology Forecast
https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hepatitis B Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis B market or expected to get launched during the study period. The analysis covers Hepatitis B market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hepatitis B Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hepatitis B Therapies and Key Companies
• AB-729: Arbutus Biopharma
• Bepirovirsen: GSK/Ionis Pharmaceuticals
• Elebsiran: Vir Biotechnology
• GSK3965193: GlaxoSmithKline
• DA-2803: Dong-A ST Co., Ltd.
• ChAdOx1-HBV: Barinthus Biotherapeutics
• Undiluted I.V.-Hepabig inj(GC5103): GC Biopharma Corp
• PEG-IFNα: Brii Biosciences Limited
• VIR-3434: Vir Biotechnology, Inc.
• AB-729: Arbutus Biopharma Corporation
• ISA104: Erasmus Medical Center
• Vemliver tablet: Daewoong Pharmaceutical Co. LTD.
• ASC22: Ascletis Pharmaceuticals
• TAF: Gilead Sciences
• GST-HG131: Fujian Akeylink Biotechnology
• TQA3605 tablets: Chia Tai Tianqing Pharma
• JNJ-73763989: Janssen Research & Development, LLC
• Nucleos(t)ide (NUC): Hoffmann-La Roche
• HRS9950 tablets: Chengdu Suncadia Medicine
• RBD1016: Suzhou Ribo Life Science
• Imdusiran: Arbutus Biopharma Corporation
• APG-1387: Ascentage Pharma Group

Discover more about therapies set to grab major Hepatitis B market share @ Hepatitis B Treatment Landscape
https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hepatitis B Market Strengths
• The high prevalence of CHB is the primary strength of its global market, leading to more focus by pharmaceutical firms.
• New diagnostic biomarkers that help identify patients with CHB have been introduced for the diagnosis.
Hepatitis B Market Opportunities
• One of the major opportunities is the new diagnostic tools or methods that can be explored for the early detection of CHB in the affected patient's pool.
• Research work can be conducted to explore more of the conventional therapeutic (NAs) methods to reduce the side effects associated with the medications for CHB.

Scope of the Hepatitis B Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hepatitis B Companies: Arbutus Biopharma, GSK/Ionis Pharmaceuticals, Vir Biotechnology, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp, Brii Biosciences Limited, Vir Biotechnology, Inc., Arbutus Biopharma Corporation, Erasmus Medical Center, Daewoong Pharmaceutical Co., Ascletis Pharmaceuticals, Gilead Sciences, Fujian Akeylink Biotechnology, Chia Tai Tianqing Pharma, Janssen Research & Development, LLC, Hoffmann-La Roche, Chengdu Suncadia Medicine, Suzhou Ribo Life Science, Arbutus Biopharma Corporation, Ascentage Pharma Group, and others
• Key Hepatitis B Therapies: AB-729, Bepirovirsen, Elebsiran, GSK3965193, DA-2803, ChAdOx1-HBV, Undiluted I.V.-Hepabig inj(GC5103), PEG-IFNα, VIR-3434, AB-729, ISA104, Vemliver tablet, ASC22, TAF, GST-HG131, TQA3605 tablets, JNJ-73763989, Nucleos(t)ide (NUC), HRS9950 tablets, RBD1016, Imdusiran, APG-1387, and others
• Hepatitis B Therapeutic Assessment: Hepatitis B current marketed and Hepatitis B emerging therapies
• Hepatitis B Market Dynamics: Hepatitis B market drivers and Hepatitis B market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hepatitis B Unmet Needs, KOL's views, Analyst's views, Hepatitis B Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.